Our clinical trials registry currently lists 54 studies:
- 32 CML studies actively recruiting patients, including
- 2 paediatric trials
- 7 treatment-free remission trials
- 20 studies that are no longer recruiting
We are pleased to share new trials from many countries worldwide, including:
- INCB84344-102 = a paediatric trial to evaluate the safety and efficacy of ponatinib in children. Two sites are actively recruiting in Belgium and Spain. Further sites will participate in Belgium, Denmark, France, Germany, Italy, Netherlands, Sweden, Spain and the United Kingdom.
- TIPI = an open trial to assess ponatinib followed by imatinib in patients with CML in chronic phase in France. There are plans to expand the inclusion criteria and open further sites in France and Switzerland if no safety warnings are detected in a preliminary assessment.
- PONAZA = an open trial to assess the efficacy and tolerance of ponatinib plus azacytidine in patients with CML in accelerated phase or in myeloid blast crisis in France. Recruitment is currently on hold for administrative reasons.
- RT51KRI03 = a trial to evaluate the efficacy and safety of radotinib as second-line treatment in patients with CML in chronic phase in South Korea. This study will also be conducted in Turkey and the Ukraine.
- RERISE China = a trial to evaluate the efficacy of radotinib as first-line treatment in patients with CML in chronic phase in China.
- ENDURE = a discontinuation trial to assess the efficacy and safety of ropeginterferon in CML patients in remission in France and Germany.
For a number of trials (KISS, PONS, ASCEMBL, ASC4MORE, CALLS, CLR_15_03), new sites were opened in the following countries:
We encourage patients as well as patient organisations to consult doctors for personal advice and further information about these studies and/or their scientific contact and study staff for the most up-to-date study information.
If you are aware of any study that is not yet listed in our Clinical Trials Register, please let us know by filling out this form. Thanks for your support!